NEW JERSEY and SHANGHAI, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today announced the acquisition of CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for worldwide (excluding Greater China) development and commercialization, from Vincentage.

CX11 is an investigational, oral small molecule GLP-1 RA for the treatment of cardiometabolic diseases, including obesity and type 2 diabetes. GLP-1 RAs have been shown to lower bodyweight, improve insulin sensitivity, and reduce glucose and overall appetite. CX11, in a once daily orally available formulation, could offer convenience and accessibility to patients, and lower the cost of manufacturing compared to injectables. In a Phase 2 clinical trial conducted in China, CX11 demonstrated competitive weight loss with favorable safety and tolerability. The registrational Phase 3 study in obese and overweight patients in China has been initiated in November 2024. CORXEL plans to initiate a global (excluding Greater China) Phase 2 study in obese and overweight patients in 2025.

kAm"~36D:EJ 92D 364@>6 2 >2;@C C:D< 724E@C 7@C 2 ?F>36C @7 49C@?:4 5:D62D6D =:<6 5:236E6D[ 9JA6CE6?D:@?[ =:G6C 5:D62D6[ 2?5 2=D@ :?4=F5:?8 42C5:@G2D4F=2C 5:D62D6D DF49 2D 962CE 5:D62D6 2?5 DEC@<6[ H9:49 2C6 E96 =625:?8 42FD6D @7 562E9 H@C=5H:56] %9:D 24BF:D:E:@? >2C<D r~#)t{'D 6IA2?D:@? @7 :ED 42C5:@>6E23@=:4 A:A6=:?6 :?E@ @36D:EJ 2?5 5:236E6D[ 2?5 H6 2C6 6I4:E65 23@FE E96 A@E6?E:2= @7 r)''[ H9:49 92D D9@H? :>AC6DD:G6 677:424J :? H6:89E C65F4E:@?[ >2<:?8 :E 2 A@E6?E:2= 36DE\:?\4=2DD @C2= D>2== >@=64F=6 v{!\' #p[" D2:5 $2?5J |@F[ q@2C5 tI64FE:G6 s:C64E@C 2?5 r9:67 tI64FE:G6 ~77:46C @7 r~#)t{] "$:?46 :ED 6DE23=:D9>6?E[ r~#)t{ 92D AC@G6? :ED DEC@?8 42A23:=:E:6D :? 2DD6E D6=64E:@?[ 4=:?:42= 56G6=@A>6?E[ C68:DEC2E:@? 2?5 A2CE?6C:?8 :? >2?F724EFC:?8 7@C :??@G2E:G6 >65:4:?6D] ~FC 8=@32= E62> :D 7F==J 4@>>:EE65 E@ 56G6=@A:?8 r)'' H:E9 9:89 BF2=:EJ 2?5 677:4:6?4J[ 2==@H:?8 r~#)t{ E@ E2A :?E@ E96 EC6>6?5@FD @36D:EJ >2C<6E H@C=5H:56]"k^Am kAm"(6 2C6 G6CJ 56=:89E65 E92E r~#)t{ H:== 36 25G2?4:?8 E96 8=@32= 56G6=@A>6?E @7 'r%aa_ Wr)''X] r~#)t{ 92D DEC@?8 4=:?:42= 56G6=@A>6?E 42A23:=:E:6D 2?5 8=@32= AC@>@E:@?2= DEC6?8E9D] (6 =@@< 7@CH2C5 E@ r~#)t{ 2446=6C2E:?8 E96 4=:?:42= EC:2=D 2?5 3C:?8:?8 E9:D :??@G2E:G6 @C2= v{!\' >@=64F=6 E@ A2E:6?ED H@C=5H:56 :? E96 7FEFC6[" D2:5 q6? {:[ r9:67 tI64FE:G6 ~77:46C @7 ':?46?E286]k^AmkAmp3@FE r~#)t{ k^AmkAmr~#)t{ :D 2 =625:?8 3:@E649 4@>A2?J 9625BF2CE6C65 :? &$ 2?5 r9:?2 7@4FD65 @? 56G6=@A:?8 :??@G2E:G6 42C5:@>6E23@=:4 E96C2A:6D 8=@32==J] r~#)t{ H2D 7@F?565 :? a_'h 2?5 92D 366? 4@>>:EE65 E@ 3C:?8:?8 :??@G2E:G6 D4:6?46 2?5 >65:4:?6D E@ F?56CD6CG65 A2E:6?ED 2C@F?5 E96 H@C=5] (:E9 2 DEC@?8 2?5 7FCE96C 56G6=@A:?8 2DD6E A:A6=:?6[ :?5FDECJ =625:?8 E2=6?E[ 2?5 A2E:6?E\46?EC:4 7@4FD[ r~#)t{ :D 565:42E65 E@ 56=:G6C:?8 2 >62?:?87F= 2?5 =2DE:?8 :>A24E @? A2E:6?ED]  k^AmkAm%96 A@CE7@=:@ @7 r~#)t{ 4@?D:DED @7 b 2DD6ED H:E9 8=@32= C:89ED 2?5 a 2DD6ED H:E9 vC62E6C r9:?2 C:89ED :? =2E6\DE286 4=:?:42= 56G6=@A>6?E] %96 A@CE7@=:@ H:E9 8=@32= C:89ED 4@G6CD r)'' 7@C @36D:EJ 2?5 5:236E6D[ y)'_ 7@C 24FE6 :D496>:4 DEC@<6 Wpx$X 2?5 y)_h 7@C 9JA6CE6?D:@?[ H9:=6 E96 A@CE7@=:@ H:E9 vC62E6C r9:?2 C:89ED :?4=F56D k6>mtEC:A2>:= k^6>m 2?5 {}+'__] k^Am kAmu@C 7FCE96C :?7@C>2E:@? 23@FE r~#)t{[ A=62D6 G:D:E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l|r#r4$;D>|&)cb|\hC%JfJ7}v8{#{t&w%fvy=_D5w'52'BHz;*r'KgJc!(}4!|(b*;|D8*a&2<'>5q'9bfdp2vq~ygA$EFGCb_589u5}+GxlQ C6=lQ?@7@==@HQmHHH]4@CI6=3:@]4@>k^2m   k^AmkAm|65:2 4@?E24Ei k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l)x#ECgvd:q~Dxc!::E0H>I3w<eK":&%bd>4F+70$'$d{y9shh{5B!0C(>6gs#()~As$B2qt8"~EaxByvp'K@;~(3?=aFw832%?a%_{z>$E4lQ C6=lQ?@7@==@HQm>65:2o4@CI6=3:@]4@>k^2mk^AmkAmp3@FE ':?46?E286 k^AmkAm':?46?E286 :D 2 4=:?:42=\DE286 3:@E649[ 7@4FD:?8 @? 56G6=@A:?8 ?@G6= D>2== >@=64F=6 5CF8D 7@C >6E23@=:4 5:D62D6D] %96 4@>A2?J 92D 56G6=@A65 D>2== >@=64F=6 :??@G2E:G6 5CF8D E2C86E:?8 5:776C6?E >6492?:D>D 2?5 E2C86ED 7@C >6E23@=:4\C6=2E65 5:D62D6D[ DF49 2D 5:236E6D[ @36D:EJ[ 2?5 |p$w] k^AmkAmk^AmkAmk^Am